Up to date in pharmacological treatment of dilated cardiomyopathy.
Dilated cardiomyopathy is a syndrome characterized by dilatation and impaired function of one or both ventricles and represents the most common heart failure entity requiring heart transplantation. The treatment we currently use does not directly influence specific underlying pathomechanisms of this disorder, and several attempts are being made in order to introduce more specific therapies. We summarized the most important pharmacological strategies that are being evaluated for the treatment of dilated cardiomyopathy and pointed out the novel therapeutic approaches concerning heart failure secondary to this clinical condition.
Ginghina
Carmen
C
Institute of Cardiovascular Disease Prof Dr C.C. Iliescu, Bucharest, Romania.
Teodorescu
Andreea
A
Stoian
Ioana
I
Serban
Marinela
M
Ghiorghiu
Ioana
I
Wohlfart
Karola
K
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D002311:Cardiomyopathy, Dilated / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D015316:Genetic Therapy; D006801:Humans; D007167:Immunotherapy; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D013148:Spironolactone / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000998:Antiviral Agents; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone